Light-Powered Chemistry Creates 3D Drug Structures to Overcome Limitations of Traditional Designs
Researchers at the University of Hong Kong developed a light-driven method to synthesize complex three-dimensional molecular frameworks as alternatives to flat benzene rings in pharmaceuticals. The technique uses visible light and specialized copper catalysts to create stable, versatile drug building blocks. This advancement could improve drug solubility, stability, and effectiveness.
Researchers at the University of Hong Kong (HKU), led by Professor Jian He, have developed a novel light-driven method using visible light and specialized copper(I) photosensitizers to synthesize bicyclo[2.1.1]hexane (BCH) molecular frameworks—three-dimensional alternatives to traditional flat benzene rings used in pharmaceuticals. Published in Nature Chemistry on August 18, 2026, the study demonstrates a catalytic photosensitization strategy that enables intermolecular cycloadditions between bicyclo[1.1.0]butanes (BCBs) and various alkenes, including electron-deficient, enyne, diene, and even aliphatic alkenes. This approach overcomes longstanding challenges in BCH synthesis, such as limited substrate scope, catalyst instability, and unwanted polymerization side reactions. The team engineered heteroleptic copper(I) complexes whose triplet energy levels can be tuned to suppress competing pathways and enhance selectivity, allowing for gram-scale production and post-synthetic functionalization of the resulting structures.
The shift from flat benzene rings—common in drugs due to their stability but often problematic for solubility and target interaction—toward 3D frameworks like BCHs represents a strategic move in medicinal chemistry. Benzene’s lipophilic nature can hinder water solubility and metabolic stability, limiting drug efficacy. BCHs offer a compact, rigid, three-dimensional scaffold that may improve these properties while maintaining structural utility. The HKU team’s
This breakthrough may reshape drug discovery by enabling chemists to design molecules with improved solubility, stability, and target specificity—key hurdles in developing effective pharmaceuticals. If scalable and adaptable across diverse compound classes, the technique could reduce reliance on benzene-based architectures, potentially lowering toxicity risks and improving bioavailability of new drugs. The use of visible light and earth-abundant copper catalysts also aligns with green chemistry principles, which may attract investment from sustainable biotech firms and regulatory bodies promoting environmentally responsible manufacturing. A comparable precedent is the rise of photoredox catalysis in the 2010s, which similarly leveraged light to access novel reaction pathways and was quickly adopted by both academia and industry. The broader impact could extend to pharmaceutical supply chains, where more efficient synthesis routes may shorten development timelines and reduce costs. How